vTv Therapeutics (VTVT) Interest Expenses (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Interest Expenses data on file, last reported at $20.7 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 15970.54% year-over-year to $20.7 million; the trailing twelve-month figure through Mar 2026 stood at $20.7 million (up 15970.54% YoY), and the FY2025 full-year result was $50.1 million, up 47.31% from the prior year.
• Interest Expenses advanced to $20.7 million in Q1 2026, from $1000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $20.7 million in Q1 2026 to a low of $1000.0 in Q4 2025.
• A 5-year average of $1.6 million and a median of $274000.0 in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses sank 97.78% in 2025 and soared 15970.54% in 2026, its largest moves.
• Tracing VTVT's Interest Expenses over 5 years: stood at $6000.0 in 2022, then climbed by 16.67% to $7000.0 in 2023, then slumped by 71.43% to $2000.0 in 2024, then tumbled by 50.0% to $1000.0 in 2025, then soared by 2073000.0% to $20.7 million in 2026.
• Business Quant data shows VTVT's Interest Expenses at $20.7 million in Q1 2026, $1000.0 in Q4 2025, and $5000.0 in Q3 2025.